(Reuters) – Valneva is on the stock market on Tuesday after announcing optimistic forecasts for 2025, while reporting a robust cash and an increase of 10% of its annual turnover.

The French Biotechnology Company declared to anticipate in 2025 a turnover between 180 and 190 million euros, as well as growth of its sales, which should reach 170 to 180 million euros.

“With more than 168 million euros in cash at the end of 2024, we tackle 2025 in a good financial position to support these objectives,” Peter Bühler, a Valneva financial director, said in a statement.

Valneva also specifies to expect a sharp drop in operating cash consumption in 2025, expected less than 30 million euros.

Throughout the year, the group recorded a turnover of 169.6 million euros, up 10% over one year, and sales of 163.3 million euros, up 13%.

On the Paris Stock Exchange, around 11:20 a.m. GMT, the title gains approximately 3.7% at 3.51 euros, against a loss of 0.40% for the SBF120 at the same time.

In a note, Suzanne Van Voorthuizen, analyst at Kempen, notes that Valneva forecasts include two good surprises: a forecast of turnover greater than expectations and a 50% drop in cash consumption.

Kempen also points out that attention will be focused in 2025 on the results of the phase 3 study for VLA15, the candidate vaccine against Lyme disease from Valneva.

“We see a high probability of success in it and, in this low valuation, an attractive risk-reversal report,” said the broker.

“The cash flow is at this stage very comfortable for the company which can largely reach the next major milestones of its development,” said Mohamed Kaabouni, analyst at Portzamparc.

(Written by Etienne Breban and Mara Vîlcu, edited by Augustin Turpin)

Copyright © 2025 Thomson Reuters